Let’s K-Talk: A Storytelling Intervention Leveraging Chatbot Technology to Prevent HPV and HPV Associated Cancers for Ethnic Koreans Living in the U.S.

项目总结/摘要 这个K23奖项的主要目标是为Minjin Kim博士提供结构化的高级研究培训， 保护时间和指导，以改善健康差距，促进健康，预防疾病， 以及利用技术改善健康和覆盖服务不足、资源不足的人群的创新。 候选人：金博士是一位跨文化的护士科学家，致力于使用叙事或 采用“讲故事”的方法，捕捉不同人群和社区的声音。她的长期目标 是设计和实施可持续的疾病预防计划，利用理论上的技术- 以减少健康差距和促进健康公平为基础，具有文化包容性和个人相关性， 改善预防性健康行为和结果，并覆盖服务不足、需求高的人群。金博士的 短期目标是利用人工智能（AI）聊天机器人进行讲故事干预， 及时、有效和持续的疫苗接种动机，以预防HPV相关感染和癌症。 研究：人乳头瘤病毒（HPV）感染是一种性传播感染，4例新感染中有3例 发生在15至24岁的个体中。虽然HPV疫苗在预防HPV相关疾病方面是安全有效的， 感染和癌症，我们的初步研究表明，只有五分之一的讲英语，受过大学教育， 美国东北部18至26岁的韩裔美国妇女接受了HPV疫苗（19%）。金博士的 利用AI聊天机器人技术（K-Talk）的基于讲故事视频的干预提供了以用户为中心的 促进18至26岁韩裔美国人HPV疫苗接种行为的经验。本研究旨在：（1） 调整和完善以前开发的K-Talk，2）进行基于多阶段优化策略的试点 评估K-Talk的可行性、可接受性和初步疗效的试验。拟议的研究评估了 通过获得HPV疫苗接种卡的照片文件来获得主要结局（HPV疫苗接种）。这 这项研究有很大的机会接触到服务不足，难以接触到的韩裔美国人和其他少数民族。 K-Talk是一种很有前途的干预措施，可以促进HPV疫苗接种作为预防癌症的一种手段。 指导/培训：利用跨学科指导团队和内部顾问的专业知识， 在辛辛那提之外，金博士将在五个领域实现她指定的研究和职业目标，以推进 她的研究计划通过这个奖项。这些领域是：设计干预研究， 最先进的研究设计，mHealth和基于聊天机器人的技术，以改善健康沟通， 传播干预措施，开展和管理临床试验和实用性试验， 临床试验数据的统计方法以及沟通和领导技能。拟议研究 培训将使金博士能够独立进行未来的实用试验（R 01）， K-Talk干预在这项提案中试点。

PROJECT SUMMARY/ABSTRACT The primary goal of this K23 award is to provide Dr. Minjin Kim with the structured advanced research training, protected time, and mentoring necessary for improving health disparities, health promotion, disease prevention, and innovation using technology to improve health and to reach underserved, under-resourced populations. Candidate: Dr. Kim is a transcultural nurse scientist dedicated to health disparities research using a narrative or “storytelling” approach to capture the voices of a diverse range of people and communities. Her long-term goal is to design and implement sustainable disease prevention programs leveraging technologies that are theory- based, culturally inclusive, and personally relevant to reduce health disparities and promote health equity, improve preventive health behaviors and outcomes, and reach underserved, high-need populations. Dr. Kim’s short-term goal is to employ storytelling interventions leveraging artificial intelligence (AI) chatbots that facilitate timely, effective, and sustained motivation for vaccination to prevent HPV-related infections and cancers. Research: Human papillomavirus (HPV) infection is a sexually transmitted infection with 3 out of 4 new infections occurring in individuals aged 15 to 24. Although HPV vaccine is safe and effective at preventing HPV-related infections and cancers, our preliminary study has shown that only 1 in 5 English-speaking, college-educated Korean American women aged 18 to 26 in the Northeast U.S. had received the HPV vaccine (19%). Dr. Kim’s storytelling video-based intervention leveraging AI chatbot technology (K-Talk) delivers a user-centered experience to promote HPV vaccination behavior among Korean Americans aged 18 to 26. The study aims to 1) adapt and refine the previously developed K-Talk and 2) conduct a pilot Multiphase Optimization Strategy-based trial to assess feasibility, acceptability, and preliminary efficacy of K-Talk. The proposed study assesses the primary outcome (HPV vaccine uptake) by obtaining photo documentation of an HPV vaccination card. This study has a substantial opportunity to reach underserved, hard-to-reach Korean Americans and other minorities. K-Talk is a promising intervention to promote HPV vaccination as a means of cancer prevention. Mentoring/Training: With the expertise of the transdisciplinary mentoring team and consultants from inside and outside of Cincinnati, Dr. Kim will achieve her appointed research and career goals in five domains to advance her program of research through this award. These domains are: designing intervention studies using state-of- the-art research design, mHealth and chatbot-based technologies to improve health communication and dissemination of the interventions, conducting and managing clinical trials and pragmatic trials, advanced statistical methods for clinical trials data as well as communication and leadership skills. The proposed research and training will enable Dr. Kim to independently conduct a future pragmatic trial (R01) that evaluates efficacy of the K-Talk intervention piloted in this proposal.